He won't answer that question, and only shows up to tell us it's gonna go down after the fact, or a day or two early.
It's easy to see the moves until the news proves you wrong and you get caught.
If you hold a core position and trade the ups and down on extra shares then you can make gains trading.
It all depends on any news when it comes and how many shares you're in for when it goes up or down.
I personally will not invest any more than what I am prepared to lose, and will only buy on major dips below 10.80
Could be any major holder, insider, hedge fund, whatever.
They are probably reducing exposure to the unknown.
Small investors are far more likely the ones who have sold completely out of their positions, but I doubt small investors are causing the current drop, as volume is pretty high over normal.
That's just my opinion, and I don't see why it matters much who it is .
The fact is, it is being sold.
I was in vicl for months after that crashed and thought it had bottomed at 1.50 so I bought another 10k shares to go with the 1k I owned at 4.0
As I averaged down to 1.75
It ended up falling to 1.01 and then rose but was unsteady until mgmt announced they bought big positions at 1.41, which caused a pop to 1.79 and I got out at 1.75 on all 11k shares.
I sold my 2k of vtus at 1.70, took the loss and would only buy back if I see something positive or the pps fall to 1.10.
That's my current plan which could change.
Any talk about the book value is meaningless in regards to a speculative biotech with no earnings or approved drug revenue.
As the cash position dwindles so will the book.
That's what they did at vicl and it has enabled the pps to hold up better at the price they bought.
The news of it caused the stock to pop to 1.79, but gradually worked it's way back down.
It was that pop that allowed me to get out at 1.75 without a loss.
Did you hear why our olympic hockey team lost the gold medal.
Does anyone care.
A loss is a loss.
Yep! These yo yo moves in the stock price are getting quite annoying, but becoming great opportunities to accumulate before the gold rush starts.
I'd really like to know what would the consensus be if the company did announce they would market this otc.
Would the pps look at that positively and increase or nosedive??
Would demand for the product be higher due to lower cost , thereby offsetting the decline in revenue??
Would you be a buyer of stock if that occurred??
The Food and Drug Administration says it’s planning to overhaul the slow and clumsy system for regulating over-the-counter drugs from aspirin to eye drops and is asking for public input.
Both drugmakers and consumer advocates have been pressing for the changes. Companies that make the products want more flexibility, while consumer watchdogs say FDA needs to move more quickly to restrict dangerous products.
Image: Cold and flu products FRED PROUSER / REUTERS FILE
Cold and flu products
FDA says it’s seeking public input and announced a two-day meeting at the end of March.
Right now, over the counter, or OTC, products are regulated mostly using what’s called a monograph — a listing of the ingredients in the product and what they are allowed to be used for. “OTC products that meet a monograph’s requirements may be marketed without FDA review,” the agency says on its website.
It’s not anywhere near as strict as the process FDA uses to approve prescription drugs, which must be tested and shown to be effective and safe. Sometimes prescription products get moved to OTC status, but usually new OTC drugs can go on the market without any testing so long as they contain recognized ingredients.
The system has been around since 1972, but it’s time-consuming and many common pain relievers and cough medicines are still technically under review, even though they are freely available on the shelves.
It worries some regulators at FDA, who would like to lower the available doses of drugs such as acetaminophen, which can cause fatal liver damage. It took FDA decades to finally take a stand against triclosan, an antibacterial ingredient in hand and dish soaps. Last month FDA finally proposed forcing manufacturers to prove that adding the ingredient was beneficial and not harmful.
“The Agency is interested in exploring ways to re-engineer the process of regulating OTC drugs that are currently regulated under the OTC Monograph Process to, among other things, create a process that is more efficient and more responsive to newly emerging information and evolving science, and to allow for more rapid product innovation where appropriate,” FDA said in announcing the meeting, to be held March 25 and 26 outside Washington D.C.